U.S. Markets closed

Looking for Value? Why It Might Be Time to Try Nucor (NUE)

Sanhita Banerjee
1 / 2

Synchrony Financial's (SYF) Earnings Surpass Estimates in Q1

Synchrony Financial's (SYF) better-than-expected Q1 earnings impress with solid loan receivable and deposit growth. However, the rising level of loan loss provision poses a risk to the stock.

Value investing is always a very popular strategy, and for good reason. After all, who doesn’t want to find stocks that have low PEs, solid outlooks, and decent dividends?

Fortunately for investors looking for this combination, we have identified a strong candidate which may be an impressive value; Nucor Corporation NUE.

Nucor in Focus

NUE may be an interesting play thanks to its forward PE of 11, its P/S ratio of 1, and its decent dividend yield of 2.5%. These factors suggest that Nucor is a pretty good value pick, as investors have to pay a relatively low level for each dollar of earnings, and that NUE has decent revenue metrics to back up its earnings.

Nucor Corporation PE Ratio (TTM)

Nucor Corporation PE Ratio (TTM) | Nucor Corporation Quote


But before you think that Nucor is just a pure value play, it is important to note that it has been seeing solid activity on the earnings estimate front as well. For current year earnings, the consensus has gone up by 11.5% in the past 30 days, thanks to four upward revisions in the past one month compared to none lower.

This estimate strength is actually enough to push NUE to a Zacks Rank #1 (Strong Buy), suggesting it is poised to outperform. You can see the complete list of today’s Zacks #1 Rank stocks here.

So really, Nucor is looking great from a number of angles thanks to its PE below 20, a P/S ratio below one, and a strong Zacks Rank, meaning that this company could be a great choice for value investors at this time.

5 Medical Stocks to Buy Now

Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.

New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.

Click here to see the 5 stocks >>
 


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Nucor Corporation (NUE) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research